Livagen
Also known as: Liver bioregulator, Lys-Glu-Asp-Ala
Livagen (also called Liver bioregulator or Lys-Glu-Asp-Ala) is a khavinson liver bioregulator. Livagen is Lys-Glu-Asp-Ala, a synthetic tetrapeptide in the Khavinson series associated with liver tissue. The series hypothesis holds that short peptides enter the nucleus and interact directly with promoter sequences, modulating transcription of tissue-relevant genes; for Livagen the reported effects concern hepatocyte protein synthesis and chromatin decondensation in lymphocyte preparations.
For research use only.
Key Facts
- CAS
- 433257-50-2
- Molecular Weight (MW)
- 461.5 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Hepatocytes (proposed)
Vendor price snapshot
Price per mg is list price divided by vial size in milligrams when both are known from public vendor listings. Peptide Library does not sell peptides. Confirm live prices on the vendor site.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg range
- $2.50/mg
Research summary
Short synthetic peptide marketed as a hepatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. Published work is largely Russian-language and class-level, and no controlled human trials evaluating this specific peptide for liver outcomes have been indexed.
Peptide Library's Livagen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C18H31N5O9 |
|---|---|
| Molecular weight | 461.5 g/mol |
| CAS number | 433257-50-2 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 87919683 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Livagen is Lys-Glu-Asp-Ala, a synthetic tetrapeptide in the Khavinson series associated with liver tissue. The series hypothesis holds that short peptides enter the nucleus and interact directly with promoter sequences, modulating transcription of tissue-relevant genes; for Livagen the reported effects concern hepatocyte protein synthesis and chromatin decondensation in lymphocyte preparations. The evidence base is cell-culture and cytogenetic work from a single research group published largely in Russian, and no controlled human trial has evaluated hepatic outcomes. No receptor has been identified.
Origin
Synthetic short peptide.
Targets
Studies
- [Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen]
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people
- [Functional morphology of an organotypic liver culture exposed to the peptide livagen]
Regulatory & research status
Livagen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Livagen: frequently asked questions
What is Livagen?
Short synthetic peptide marketed as a hepatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. Published work is largely Russian-language and class-level, and no controlled human trials evaluating this specific peptide for liver outcomes have been indexed.
How does Livagen work?
Livagen is Lys-Glu-Asp-Ala, a synthetic tetrapeptide in the Khavinson series associated with liver tissue. The series hypothesis holds that short peptides enter the nucleus and interact directly with promoter sequences, modulating transcription of tissue-relevant genes; for Livagen the reported effects concern hepatocyte protein synthesis and chromatin decondensation in lymphocyte preparations.
Is Livagen FDA approved?
No. Livagen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Livagen?
Compounds most often compared with Livagen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen] — Georgian Med News, 2007External reference
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages] — Adv Gerontol, 2005External reference
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum] — Izv Akad Nauk Ser Biol, 2003External reference
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people — Bull Exp Biol Med, 2002External reference
- [Functional morphology of an organotypic liver culture exposed to the peptide livagen] — Adv Gerontol, 2002External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Livagen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Livagen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →